Neues zu Prävention und Therapie der diabetischen Nephropathie

Zusammenfassung

Die Reduktion mikro- und makrovaskulärer Endpunkte bei Patienten mit Diabetes mellitus Typ 2 erfolgt über die Kontrolle traditioneller Risikofaktoren wie Hyperglykämie, Hyperlipidämie, Übergewicht und Hypertonie. Hierbei ist zu beachten, dass die meisten blutzuckersenkenden Medikamente renal eliminiert werden. Zur Vermeidung von Hypoglykämien und anderen Nebenwirkungen (wie z.B. der Laktatazidose bei Metformin) ist daher bei Patienten mit diabetes-assoziierter chronischer Nierenerkrankung eine an die Nierenfunktion angepasste Pharmakotherapie erforderlich.

Abstract

The reduction of micro- and macrovascular end points in patients with diabetes mellitus type 2 is achieved by control of traditional risk factors such as hyperglycemia, hyperlipidemia, obesity and hypertension. However, most of the glucose lowering medication available is excreted by the kidney. Thus, in patients with diabetes-associated chronic kidney disease, the glucose lowering therapy has to account for renal function to avoid hypoglycemic episodes and other side effects such as lactic acidosis due to metformin.

Schlüsselwörter

Diabetes mellitus Typ 2 - Diabetesassoziierte chronische Nierenerkrankung - Blutzuckersenkende Medikamente - Metformin - Laktatazidose

Keywords

diabetes mellitus type 2 - diabetes associated chronic kidney disease - glucose lowering drugs - metformin - lactic acidosis

• Literatur

• 1 Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 2014; 63 (2 Suppl 2) S3-21
• 2 ADA. Standards of medical care in diabetes--2015: summary of revisions. Diabetes Care 2015; 38 (Suppl: S4)
• 3 Rheinberger M, Böger CA. Diabetische Nephropathie: Neues in Diagnose, Prävention und Therapie. Dtsch Med Wochenschr 2014; 139: 704-746
• 4 BÄK, KBV, AWMF. Nierenerkrankungen bei Diabetes im Erwachsenenalter. 2010. www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/nvl-001dl_S3_Nierenerkrankungen_bei_Diabetes_Erwachsene_2013-05_01.pdf (Letzter Zugriff: 7.12.2015)
• 5 National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012; 60: 850-86
• 6 Xie X, Atkins A. Effects of intensive blood pressure lowering on cardiovascular an renal outcomes: updated systematic review and meta-analysis. Lancet 2015;
• 7 The SPRINT Research Group. A randomized Trial of Intensiv versus Standard Blood-Pressure Control. N Engl J Med 2015; 373: 2103-2116
• 8 Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
• 9 Anonym. Evolocumab (Repatha) – a second PCSK9 Inhibitor to lower LDL-Cholesterol. JAMA 2015; 314: 2298-2299
• 10 Gregg EW, Chen H, Wagenknecht LE et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308: 2489-2496
• 11 Look Ahead Research Group et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
• 12 Look Ahead Research Group, Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2: 801-809
• 13 Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3: 866-875
• 14 Eliasson B, Liakopoulos V, Frenzén S et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol 2015; 3: 847-854
• 15 Sjostrom L, Peltonen M, Jacobson P et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297-2304
• 16 KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf (Letzter Zugriff: 4.12.2015)
• 17 Papademetriou V, Lovato L, Doumas M et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 2015; 87: 649-659
• 18 Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis 2014; 63 (2 Suppl 2) S22-38
• 19 Inzucchi SE, Lipska KJ, Mayo H et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312: 2668-2675
• 20 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206
• 21 Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128